Prostate Cancer

Emerging research highlights disparities in the diagnosis, treatment, and quality-of-life outcomes of prostate cancer in sexual minorities, emphasizing the urgent need for more culturally responsive healthcare practices. Further studies will provide healthcare professionals with the necessary tools to deliver better care to these underrepresented patient populations. Prostate cancer affects men across all sexual orientations, yet...

Fascin-1 has a promising role as a biomarker in urologic cancers. Metastasis is the leading cause of poor prognosis in urologic cancers. Early diagnosis and effective treatments for metastatic cancer would improve the survival rate. Fascin-1 is an actin-binding protein involved in cell division, migration, and intercellular interactions. There is frequent upregulation of fascin-1 in...

This analysis explores the intricate relationship between continuity of care and treatment outcomes in advanced prostate cancer patients within the Medicare system. Specifically, it sheds light on the impact of racial disparities on these healthcare dynamics, offering fresh insights for improved patient care strategies. Higher continuity of care is linked to reduced emergency room visits,...

A recent large-scale study investigated the use of comprehensive genomic profiling and treatment patterns across ancestries to determine their impact on ancestral disparities in advanced prostate cancer. The research provides crucial insights into the genomic landscape and clinical treatment patterns in diverse ancestries, focusing on African and European backgrounds. Advanced prostate cancer genomics and treatment...

In light of persistent racial disparities in prostate cancer care, a recent review discusses current understanding and future directions towards a more equitable healthcare approach. Highlighting the importance of social determinants of health, the study points to potential strategies for improving the standard of care for marginalized communities. Disparities in prostate cancer care are well...

A new study examines the combination of olaparib and abiraterone in treating metastatic castration-resistant prostate cancer, suggesting possible benefits and implications for patient selection and treatment strategies. The PROpel trial explores the use of olaparib and abiraterone as first-line treatment for metastatic castration-resistant prostate cancer. Combination therapy shows longer progression-free survival compared to hormonal treatments...

Researchers have demonstrated a novel imaging technique known as dual probe difference specimen imaging, that could significantly improve the assessment of tumor margins during prostate cancer surgery. Uses spectrally distinct fluorophores paired with targeted and untargeted probes to rapidly and accurately assess prostate-specific membrane antigen status. This method overcomes limitations of current intraoperative tumor margin...

Staff Writer: Andre McGowan Stronger diet effect seen in Gleason grade group >6 and in International Society of Urological Pathology grade 3 + 4 + 5 tumors.   Adherence to a Western diet may have a detrimental effect on the risk for prostate cancer, according to a study published online April 19 in BJU International....

Rural–urban disparities in prostate cancer outcomes are relatively clear. This study describes patient care experiences among rural and urban patients, as well as how they impact outcomes. Patients who live in rural areas tend, on average, to have poor access to healthcare. As a result, they tend to exhibit worse outcomes, and to have lower...